195 related articles for article (PubMed ID: 31022310)
21. PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling.
Wang YH; Chen D; Hartmann G; Cho CR; Menzel K
Clin Pharmacol Ther; 2019 Feb; 105(2):515-523. PubMed ID: 29901213
[TBL] [Abstract][Full Text] [Related]
22. Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.
Cho JC; Le AD; Locke SC
Drugs Today (Barc); 2018 Jun; 54(6):361-368. PubMed ID: 29998227
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
24. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
[TBL] [Abstract][Full Text] [Related]
25. The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevir.
Guo Z; Caro L; Robertson MN; Hwang P; Hoover P; Wudarski C; Maiuri K; Wang YH; Mogg R; Mehrotra DV; Blanchard R; Shaw PM
Pharmacogenomics; 2019 Jun; 20(9):631-641. PubMed ID: 31250727
[No Abstract] [Full Text] [Related]
26. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
[TBL] [Abstract][Full Text] [Related]
27. Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.
Maeda A; Ando H; Ura T; Komori A; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Kobara M; Matsuzaki M; Hashimoto N; Maeda M; Kojima Y; Aoki M; Kondo E; Mizutani A; Fujimura A
Int J Clin Pharmacol Ther; 2017 May; 55(5):409-415. PubMed ID: 28157071
[TBL] [Abstract][Full Text] [Related]
28. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
Oh ES; Kim CO; Cho SK; Park MS; Chung JY
Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
[TBL] [Abstract][Full Text] [Related]
29. Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations.
Lin R; Wang X; Wang Y; Zhang F; Wang Y; Fu W; Yu T; Li S; Xiong M; Huang W; Jin L
Hum Mutat; 2009 Apr; 30(4):609-15. PubMed ID: 19243019
[TBL] [Abstract][Full Text] [Related]
30. The frequency of major
Alrajeh K; AlAzzeh O; Roman Y
Pharmacogenomics; 2023 May; 24(7):381-398. PubMed ID: 37222158
[TBL] [Abstract][Full Text] [Related]
31. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.
Ieiri I; Suwannakul S; Maeda K; Uchimaru H; Hashimoto K; Kimura M; Fujino H; Hirano M; Kusuhara H; Irie S; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2007 Nov; 82(5):541-7. PubMed ID: 17460607
[TBL] [Abstract][Full Text] [Related]
32. Effect of letermovir on levonorgestrel and ethinyl estradiol pharmacokinetics
.
Adedoyin A; Cho CR; Fox-Bosetti S; Macha S; Zhao T; Liu F; Panebianco D; O'Reilly TE; McCrea J; Stoch SA; Iwamoto M
Int J Clin Pharmacol Ther; 2019 Sep; 57(9):450-457. PubMed ID: 31232280
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers.
Scheuenpflug J; Kropeit D; Erb-Zohar K; Theis JGW; Stobernack HP; McCormick D; Zimmermann H; Rübsamen-Schaeff H
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):6-15. PubMed ID: 34812580
[TBL] [Abstract][Full Text] [Related]
34. Genome-Wide Association Study of Atorvastatin Pharmacokinetics: Associations With SLCO1B1, UGT1A3, and LPP.
Mykkänen AJH; Tarkiainen EK; Taskinen S; Neuvonen M; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Klein K; Schwab M; Backman JT; Tornio A; Niemi M
Clin Pharmacol Ther; 2024 Jun; 115(6):1428-1440. PubMed ID: 38493369
[TBL] [Abstract][Full Text] [Related]
35. Effects of genetic variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of telmisartan in Chinese patients with mild to moderate essential hypertension
.
Pei Q; Yang L; Tan HY; Liu SK; Liu Y; Huang L; Li RH; Wan Q; Huang J; Guo CX; Zuo XC; Li J; Yang GP
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):659-665. PubMed ID: 28518053
[TBL] [Abstract][Full Text] [Related]
36. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics.
Katz DA; Carr R; Grimm DR; Xiong H; Holley-Shanks R; Mueller T; Leake B; Wang Q; Han L; Wang PG; Edeki T; Sahelijo L; Doan T; Allen A; Spear BB; Kim RB
Clin Pharmacol Ther; 2006 Mar; 79(3):186-96. PubMed ID: 16513443
[TBL] [Abstract][Full Text] [Related]
37. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects.
Kropeit D; von Richter O; Stobernack HP; Rübsamen-Schaeff H; Zimmermann H
Clin Pharmacol Drug Dev; 2018 Jan; 7(1):9-21. PubMed ID: 28967706
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
40. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.
Marty FM; Ljungman P; Chemaly RF; Maertens J; Dadwal SS; Duarte RF; Haider S; Ullmann AJ; Katayama Y; Brown J; Mullane KM; Boeckh M; Blumberg EA; Einsele H; Snydman DR; Kanda Y; DiNubile MJ; Teal VL; Wan H; Murata Y; Kartsonis NA; Leavitt RY; Badshah C
N Engl J Med; 2017 Dec; 377(25):2433-2444. PubMed ID: 29211658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
